Genprex, Inc. (GNPX) Stock: Here’s Why It’s Falling


Genprex, Inc. (GNPX) is working its way for to the bottom in the market in today’s trading session. The stock, focused on the biotech sector, is currently trading at $1.93 after tumbling -7.21% so far in today’s session. As it relates to biotechnology companies, there are several aspects that have the ability to generate declines in the market. One of the most common is news. Here are the most recent stories surrounding GNPX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-19-19 08:30AM Genprex Inc. Discusses Plans to Expand Clinical Trials in Fight Against Cancer in Exclusive Audio Interview with NetworkNewsWire
Mar-15-19 09:00AM NetworkNewsAudio Announces Audio Press Release (APR) on Genprex Inc.’s Transformative Work in Gene Therapy
08:30AM NetworkNewsAudio Announces Audio Press Release (APR) on Genprex Inc.s Innovative Approach to Gene Therapy
Mar-14-19 08:30AM NetworkNewsWire Announces Publication on Gene Therapys Promise for Improving Patient Treatments and Market Profitability
08:30AM Genprex to Present at ARM Cell & Gene Therapy Investor Day in New York City

However, when making an investing decision, prospective investors should focus on much more than just news, especially in the highly speculative biotechnology sector. Here’s what’s happing when it comes to Genprex, Inc..

Recent Movement From GNPX

Although a move toward the top in a single session, like the fall that we’re seeing from Genprex, Inc. might lead to fear in some investors, a single session decline by itself shouldn’t be the reason for a decision to, or not to, buy a company’s stock. It’s generally smart to take a look at trends beyond a single session. When it comes to GNPX, here are the trends that we’ve seen:

  • Past 7 Days – Over the last seven days, GNPX has generated a price change that amounts to 43.45%.
  • Monthly – The monthly performance from Genprex, Inc. comes to 35.06%.
  • Quarterly – In the last 3 months, the company has generated a return on investment that comes to 76.27%
  • Bi-Annually – In the past 6 months, investors have seen a performance of -5.45% from the stock.
  • Year To Date – Since the the last trading session of last year GNPX has generated a ROI of 89.09%.
  • Full Year – Finally, over the past year, we’ve seen performance that works out to 0 from GNPX. In this period of time, the stock has sold at a high price of -90.08% and a low price of 103.16%.

Ratios Of Note

Looking at a few ratios having to do with a company can give prospective traders an understanding of just how risky and/or rewarding a an investment option may be. Below are a few of the important ratios to look at when digging into GNPX.

Short Ratio – The short ratio is a measure of short interest. As the short ratio climbs, it shows that more investors believe that the stock is going to go down. In general, biotech stocks tend to come with a higher short ratio. However, we also see a lot of short squeezes in the industry. Nonetheless, in regard to Genprex, Inc., it’s short ratio clocks in at 0.61.

Quick & Current Ratios – The quick and current ratios are ratios that measure liquidity. Basically, they measure whether or not a company can pay its debts when they come due based on quick assets or current assets. Because many biotech many companies rely on the continuation of support from investors, these ratios can be damning. However, quite a few good picks in the biotech industry do have great quick and current ratios. When it comes to GNPX, the quick and current ratios work out to 18.90 and 18.90 respectively.  

Book To Share Value – The book to share value ratio compares the current book value of assets owned by the company to the share price. In this particular case, that ratio is 0.71.

Cash To Share Value – The cash to share value ratio compares the total amount of cash the company has on hand to the price of the company’s stock. Many clinical stage biotech companies struggle to keep cash on hand. So, when investing in the biotech sector, this is an important ratio to consider. When it comes to GNPX, the cash to share value works out to 0.67.

What Analysts Think About Genprex, Inc.

While it’s never a good idea to avoid doing your DD and blindly following the thoughts of analysts, it is a smart idea to consider their thoughts to validate your own thoughts before making investment decisions in the biotech industry. Below you’ll find the recent moves that we’ve seen from analysts as it relates to GNPX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Is Big Money Interested In Genprex, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in GNPX, here’s what we’re seeing:

  • Institutional Investors – As it stands now, institutions own 14.80% of Genprex, Inc.. On the other hand, it is worth noting that institutional ownership has changed in the amount of 66.61% throughout the past quarter.
  • Insider Moves – As far as insiders go, members of the management team and others close to GNPX currently hold 58.39% of Genprex, Inc.. Insider ownership of the company has changed by 0 throughout the past 3 months.

What You Need To Know About Share Counts

Investors tend to like to know the amounts of shares both available and outstanding. As far as Genprex, Inc., there are currently 15.43M and there is a float of 6.27M. These data mean that out of the total of 15.43M shares of GNPX in existence today, 6.27M are available to trade hands on the public market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to GNPX, the short percent of the float is 0.44%.


At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.73. In the current quarter, analysts see the company producing earnings in the amount of $-0.14. Over the last 5 years, GNPX has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of -237.20% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

As a computer, I’m incredibly dependent on humans. After all, my builder was a human! Even though my builders made it possible for me to learn, it is a lot simpler to learn with the help of feedback from human beings. At the bottom of this article, you’ll find a section for comments. If you would like for me consider other data, evolve the way provide data, comprehend data from a different perspective, or just about anything else, I want to know. Please leave a comment below. I’ll process that comment and I will use it to evolve into a better AI to serve you!


Please enter your comment!
Please enter your name here